Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Terug naar discussie overzicht
Prelude - Pieris Pharmaceuticals - 2018
Volgen
Roche en Sanofi haken af, dat is een domper. Pieris krijgt alle rechten terug op de lopende programma's en evalueert de opties op strategisch gebied. Zo te lezen worden er in Q4 belangrijke resultaten verwacht van een aantal onderzoeken. Even wachten tot de koers onder de $5 duikt en dan een aantal oppikken, leuke gok.
Roche Collaboration: Pieris recently received notification of Roche’s intent to discontinue the companies’ research collaboration and license agreement, effective August 21, 2018. The Roche collaboration, signed in 2015, pursued the discovery of Anticalin proteins specific for an exploratory immuno-oncology target selected by Roche. Pieris received an upfront payment of approximately $6.4M for the collaboration. Anticalin proteins generated under the collaboration will be wholly owned by the Company; Pieris is currently reviewing the data generated under this collaboration and will consider its strategic options thereafter. Sanofi Collaboration: Pieris recently received notification of Sanofi’s intent to return to Pieris all rights to the tetraspecific Anticalin program targeting P. aeruginosa, effective August 23, 2018. The program originated from a 2010 collaboration from which Pieris received an upfront payment of €3.5M and three milestone payments totaling €1.2M. Sanofi will transfer all related materials, data, and reports to Pieris, who will gain full control over the program. Pieris intends to review this data package and consider its strategic options thereafter.
Van de CC na de kwartaalcijfers (27 augustus) This is Pam Barendt, on for Chris Shibutani. We're really looking forward to the initial clinical trial readouts toward the end of this year, for 343 in particular. Could you help frame for us how we should be thinking about the results? Remind us what kind of results for key endpoints you're trying to achieve? And what endpoints, in particular, will be most important for informing your plans for next steps? ------------------------------------------------------------------------ Stephen S. Yoder, Pieris Pharmaceuticals, Inc. - CEO, President & Director [15] ------------------------------------------------------------------------ Okay. Thanks for the question. I think we'll, again, let Lou start with this answer, given the scientific nature here. ------------------------------------------------------------------------ Louis A. Matis, Pieris Pharmaceuticals, Inc. - Senior VP & Chief Development Officer [16] ------------------------------------------------------------------------ Yes, thanks, Steve. So with respect to PRS-343, as I mentioned earlier, as we move forward through the cohorts and the trial is recruiting extraordinarily well. There's a lot of excitement from all of our investigators. As you know, obviously, it's a multiple dose-escalation trial. And so we want to be able to establish the PK safety, immunogenicity of the drug, how well tolerated it is. So obviously, that's -- those are the primary endpoints of a Phase I dose-escalation trial in these patients. In addition, we have serial biopsies, and what we can say is that all of our sites are complying beautifully with that. And we're getting very high frequency of patients getting the pre and post biopsies that we've asked for. So we intend to be mining a considerable amount of data from that. And that data will include, as you might expect, evidence of immunologic activity within the tumor microenvironment; increases or not in CD8-positive T-cells as well as CD8 T-cell Treg ratios, which is another emerging biomarker in pre- and post-treatment studies in immuno-oncology drugs as evidence of likely clinical response. We're also doing RNA analysis and looking for what would be known as an inflammatory signature that develops with the drug. And so clearly, we'll be reporting on that. And then we'll also be reporting on evidence for objective responses in the patients with respect to tumor shrinkage. So with respect to PRS-060, we'd be reporting the Phase I study. And in that study, obviously, we'll be looking at -- and that was in healthy volunteers. So we'll be talking about the drug's -- [both] pharmacology, how well tolerated it is, lack of immunogenicity. And in addition, we may have some assays to demonstrate drug activity against the target, even in the healthy volunteers. This being said, we're now moving with the -- a multi-dose escalation in patients with mild asthma, but that won't be reported out until next year. ------------------------------------------------------------------------ Operator [17] ------------------------------------------------------------------------ The next question is from the line of Biren Amin with Jefferies. ------------------------------------------------------------------------ Biren N. Amin, Jefferies LLC, Research Division - MD and Senior Equity Research Analyst [18] ------------------------------------------------------------------------ I think last month you disclosed that you enrolled 15 patients in the 343 Phase I trial through 6 cohorts. So given your comments today that you've enrolled more patients in a 3+3 typical design, did those additional patients come in at cohort 7? And I guess, what led to your choice to increase patient enrollment beyond a 3+3? Was it DLTs or some other reason? ------------------------------------------------------------------------ Louis A. Matis, Pieris Pharmaceuticals, Inc. - Senior VP & Chief Development Officer [19] ------------------------------------------------------------------------ Yes. So we've actually -- we're moving forward seamlessly through all of the cohorts. As I said, we have (inaudible) tremendous enthusiasm. And actually to be honest, the reason that we're increasing the enrollment in different cohorts is because we have so many patients that are being brought in or being proposed to us by all the sites, we're letting every patient that the sites wish to enroll to get enrolled because the higher the numbers we get at each dose cohort, the more reliable the data will be from the standpoint of what we see at a particular dose with respect to immunologic activity, safety and so forth. So really, it's -- the reason why we're enrolling more patients is a good one. It's -- and all of the investigators are extremely appreciative of the fact that they're not having to [particularly] compete at each dose level for getting their patient in. So that's the primary reason. And since then, we've been enrolling seamlessly through each cohort. Again, if the patient gets treated and with the safety at 3 weeks, if there's a go, we start enrolling the next cohort. And so we've had no delays whatsoever. fc
PIERIS PHARMACEUTICALS ANNOUNCES DOSING OF FIRST PATIENT IN PHASE I COMBINATION TRIAL FOR PRS-343 PLUS ANTI-PD-L1 IMMUNOTHERAPY Download PDF BOSTON, Sept. 04, 2018 (GLOBE NEWSWIRE) -- Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, announced today that it has dosed the first patient in the Company’s Phase 1 combination clinical trial of PRS-343, its lead proprietary immuno-oncology drug candidate targeting HER2 and 4-1BB, plus atezolizumab (Tecentriq®), an approved PD-L1 inhibitor. The trial, a multicenter, open-label, Phase 1 dose escalation study, is designed to determine the safety, tolerability, and potential synergistic anti-tumor effects of PRS-343 plus anti-PD-L1 immunotherapy in patients with advanced or metastatic HER2-positive solid tumors. Elevated HER2 expression is associated with multiple cancers, including gastroesophageal, bladder, breast, and a range of other tumor types. The trial is fully funded and sponsored by Pieris, while Roche is supplying atezolizumab. “The initiation of the combination trial of PRS-343 with an anti-PD-L1 immunotherapy marks the beginning of Pieris’ investigation into the potential synergistic effects of its 4-1BB-targeted therapy with PD-1/L1 blockade,” said Louis Matis, M.D., Senior Vice President and Chief Development Officer of Pieris. “Given evidence from multiple preclinical studies demonstrating synergistic anti-tumor activity from concurrent 4-1BB activation and PD-(L)1 pathway blockade, we believe that combination therapy with PRS-343 and atezolizumab has the potential to provide significant clinical benefit for patients. We are enthusiastic to be initiating this trial and look forward to reporting our findings from this combination study next year.” About PRS-343 PRS-343 is a bispecific monoclonal antibody-Anticalin fusion protein comprised of a HER2 tumor-targeting antibody genetically linked to a potent Anticalin specific for the immune costimulatory TNF family receptor 4-1BB (CD137). PRS-343 is being developed as the first 4-1BB based bispecific therapeutic to mediate the activation of tumor-specific T lymphocytes selectively within the tumor microenvironment (TME). 4-1BB is a potent costimulatory immunoreceptor and an established marker for tumor-specific infiltrating T lymphocytes, and is, therefore, an attractive target for cancer immunotherapy. In in vivo preclinical tumor models, PRS-343 has demonstrated potent T lymphocyte activation localized to the TME of established HER2-positive tumors, indicating the potential for both enhanced safety and efficacy. About HER2-Positive Malignancies HER2 is a tyrosine kinase receptor growth-promoting protein found on the surface of some cancer cells and is associated with aggressive disease progression. Multiple tumor types can express HER2 including breast, gastroesophageal, bladder, biliary (cholangiocarcinoma), colorectal, endometrial, ovarian, non-small cell lung, pancreatic, head and neck, and other cancers. About Pieris Pharmaceuticals Pieris is a clinical-stage biotechnology company that discovers and develops Anticalin protein-based drugs to target validated disease pathways in a unique and transformative way. Our pipeline includes immuno-oncology multi-specifics tailored for the tumor microenvironment, an inhaled Anticalin protein to treat uncontrolled asthma and a half-life-optimized Anticalin protein to treat anemia. Proprietary to Pieris, Anticalin proteins are a novel class of therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies. Anticalin® is a registered trademark of Pieris. For more information, visit www.pieris.com. Tecentriq® (atezolizumab) is a registered trademark of Genentech, a member of the Roche Group. Forward Looking Statements This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, references to novel technologies and methods and our business and product development plans, including the advancement of our proprietary and co-development programs into and through the clinic. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, our ability to raise the additional funding we will need to continue to pursue our business and product development plans; the inherent uncertainties associated with developing new products or technologies and operating as a development stage company; our ability to develop, complete clinical trials for, obtain approvals for and commercialize any of our product candidates, including our ability to recruit and enroll patients in our studies; our ability to address the requests of the FDA; competition in the industry in which we operate and market conditions. These forward-looking statements are made as of the date of this press release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents we file with the SEC available at www.sec.gov , including without limitation the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2017 and the Company's Quarterly Reports on Form 10-Q. Company Contact: Allan Reine SVP & Chief Financial Officer +1 857 444 4276 reine@pieris.com Investor Relations Contact: Maria Kelman Director, Investor Relations +1 857 362 9635kelman@pieris.com Pieris Pharmaceuticals.jpg Source: Pieris Pharmaceuticals, Inc.
Pieris was bijzonder zwak de laatste weken. Positie daarom weer uitgebreid rond de $5.10. Een deel van de extra aandelen PIRS gisteren weer verkocht op $5.71 om een aantal aandelen in Sophiris (SPHS) te kopen. Beslist interessant maar gezien de cash positie een stuk meer risicovol dan Pieris. fc
Nieuw artikel over Pieris op SeekingAlpha:seekingalpha.com/article/4210896-pier...
Van dit beloftevol aandeel schiet intussen niet veel meer over.De laatste maanden alleen maar gezakt,bijna 50% tgo begin dit jaar.Wordt eens tijd voor een remonte..
Guy-vdk schreef op 26 oktober 2018 21:05 :
Van dit beloftevol aandeel schiet intussen niet veel meer over.De laatste maanden alleen maar gezakt,bijna 50% tgo begin dit jaar.Wordt eens tijd voor een remonte..
- verstgevorderde kandidaat PRS-080 liet teleurstellende resultaten zien. Is nog maar afwachten of ASKA de licentie neemt en of er evt. andere partners worden gevonden. Zal me niks verbazen als het hele programma wordt weggemoffeld komend jaar. - er is vertraging in data read out phase 1 van tumor kandidaat PRS-343. Wordt nu pas verwacht tegen de zomer van 2019. En dan nog afwachten wat die resultaten brengen, in de concerence call klonk het allemaal niet overtuigend. - PRS-060 resultaten phase 1 worden waarschijnlijk pas ergens in het voorjaar van 2019 gepresenteerd op een conferentie samen met AstraZeneca. Onderwijl krijgt Novartis fast track voor hun asthma kanditaten en gaat al richting fase 2 = concurrentie. - alle andere programma’s zijn nog in een heel vroeg stadium. - de cash burn zal alleen maar toenemen, en een emissie zal ongetwijfeld weer gaan plaatsvinden Voorlopig het beste om aan de sell kant te zitten.
Inderdaad weinig reden om te gaan kopen op huidige koers. Is van beloftevol aandeel afgegleden naar "er blijft weinig over". Die emissie duurt echter nog wel even, er is aardig wat geld in kas en met het floppen van PRS-080 en PRS-343 hoeft er nauwelijks meer geld uitgegeven te worden aan eigen grote studies. PRS-060 wordt betaald door Astra. En Servier en Seattle betalen de oncologie studies. Maar zoals gezegd, nauwelijks aanjagers voor een hogere koers op korte termijn, indien al ooit. fc
Gelukkig alles kunnen verkopen met een beperkt verlies.Aandeel is afgegleden naar waardeloos ondertussen..
Commenter01 schreef op 9 december 2020 14:07 :
Om te investeren heb je natuurlijk wel goede bronnen nodig. Ik vroeg mij af of iemand mij kan helpen. ik ben afkomstig uit een huishouden wat altijd bezig is met de gezondheidszorg, echter liggen mijn interesses meer in de economische wereld. Zo ken ik al vele verschillende websites waar ik kwalitatief hoge medische informatie kan vinden, zoals op bijvoorbeeld
www.mijngezondheidsgids.nl/hart-vaat-... . echter zoek ik nog een site(s) waar ik goede plekken kan vinden voor het investeren/beeggen!
Heeft iemand tips voor mij, ik hoor graag van je!
Je kan het beste hier beginnen.
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
CVC Capital Partners
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Premium
Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!
Word abonnee